The bio-tech market has been closely following Chevron Corporation (CVX). CVX has exited its North Sea operations in the UK and is gearing up to sell off its remaining assets. Despite this, its stock value has risen 0.6%. The status of CVX's $53 billion acquisition of Hess has been questioned. In spite of that, there's strong institutional backing for CVX with 67% ownership. Nonetheless, a short squeeze alert for CVX has been issued. Q1 results reveal increased U.S. production making CVX an attractive investment. Meanwhile, **dividend** analysis shows CVX to be a part of the Dividend Aristocrats Group. Higher assays are forecasting a 27% upside, setting a new target at $205. However, Q1 results also note lower refining margins and natural gas prices. Partnerships formed with **ION Clean Energy**, Accelera and Eliis reflect a strategic shift towards clean energy and advanced tech solutions. Lastly, CVX is found to be trending among investors with a promising EPS growth potential.
Chevron Corporation CVX News Analytics from Sun, 10 Sep 2023 07:00:00 GMT to Sun, 19 May 2024 08:23:08 GMT -
Rating 5
- Innovation 0
- Information 5
- Rumor -4
